Expertise in
10
conditions

Dr. Allan Pantuck

Urology
Center For Women's Pelvic Health At UCLA
200 UCLA Medical Plz Ste 140, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
10
conditions
Center For Women's Pelvic Health At UCLA
200 UCLA Medical Plz Ste 140, 
Los Angeles, CA 

Overview

Allan Pantuck is a Urologist in Los Angeles, California. Dr. Pantuck is highly rated in 10 conditions, according to our data. His top areas of expertise are Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Urology

Licenses

Urology in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Center for Women's Pelvic Health at UCLA
200 UCLA Medical Plz Ste 140, Los Angeles, CA 90095
Other Locations
Office
200 Medical Plz, Los Angeles, CA 90095

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: January 06, 2026
Intervention Type: Other
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 3
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: October 19, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)
Enrollment Status: Completed
Publish Date: April 10, 2019
Intervention Type: Drug, Diagnostic test
Study Phase: Phase 3
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
A Phase 1/2, Open-Label, Uncontrolled, Multiple-Dose Escalation, Cohort Expansion And Extension Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of ASN001 In Subjects With Metastatic Progressive Castrate Resistant Prostate Cancer
Enrollment Status: Terminated
Publish Date: March 07, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 5 Less Clinical Trials

121 Total Publications

Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.
Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches.
Journal: Clinical Medicine Insights. Oncology
Published: July 05, 2024
Similar Doctors
Expertise in
40
conditions
Dr. Siamak Daneshmand
Urology
Expertise in
40
conditions
Dr. Siamak Daneshmand
Urology

Office

1516 San Pablo St Ste 3500, 
Los Angeles, CA 
 (13.4 miles away)
323-865-3700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Siamak Daneshmand is a Urologist in Los Angeles, California. Dr. Daneshmand is highly rated in 40 conditions, according to our data. His top areas of expertise are Bladder Cancer, Muscle Invasive Bladder Cancer, Testicular Cancer, Cystectomy, and Bladder Reconstruction.

Expertise in
24
conditions
Dr. Karim Chamie
Urology
Expertise in
24
conditions
Dr. Karim Chamie
Urology

Office

200 Medical Plz, 
Los Angeles, CA 
 (0.1 miles away)
310-794-7700
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Karim Chamie is a Urologist in Los Angeles, California. Dr. Chamie is highly rated in 24 conditions, according to our data. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Cystectomy.

Expertise in
31
conditions
Dr. Mihir Desai
Urology
Expertise in
31
conditions
Dr. Mihir Desai
Urology

Mihir Desai, MD

1441 Eastlake Ave Ste 7416, 
Los Angeles, CA 
 (9.6 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mihir Desai is a Urologist in Los Angeles, California. Dr. Desai is highly rated in 31 conditions, according to our data. His top areas of expertise are Bladder Cancer, Enlarged Prostate (BPH), Renal Cell Carcinoma (RCC), Aquablation, and Nephrectomy. Dr. Desai is currently accepting new patients.

Frequently Asked Questions about Dr. Allan Pantuck

How do I make an appointment with Dr. Allan Pantuck?

You can book an appointment with Dr. Allan Pantuck by calling their office at 310-794-7700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Allan Pantuck a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Allan Pantuck is classified as an Elite expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Allan Pantuck specialize in?

While Dr. Allan Pantuck is a Urology, they have specific expertise in Renal Cell Carcinoma (RCC), Chromophobe Renal Cell Carcinoma, and Nephrectomy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Allan Pantuck participate in research or clinical trials?

Yes. Dr. Allan Pantuck has published 121 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. Allan Pantuck's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Allan Pantuck accept my insurance?

Dr. Allan Pantuck accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-794-7700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Pantuck's expertise for a condition
ConditionClose
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile